Early daratumumab or immunomodulatory agents in high-risk smoldering multiple myeloma show uncertain benefits versus observation.
Early Drug May Delay Multiple Myeloma
This systematic review evaluated early intervention with monoclonal antibodies, immunomodulatory agents, or alkylating agents versus observa…
Imagine waking up with a headache. You take a pill, and the pain goes away.
Observational study explores daratumumab resistance mechanisms in primary light-chain amyloidosis
Small study links daratumumab resistance to immune changes in light-chain amyloidosis
An observational cohort study of 30 patients with primary light-chain amyloidosis treated with daratumumab-bortezomib-dexamethasone found th…
Patients with weaker responses to amyloidosis treatment showed lower gene activity before therapy and increased immune stress during treatme…
Daratumumab + Len/Dex shows ORR in relapsed/refractory multiple myeloma phase 1/2 trial
Can a new drug combination help people with multiple myeloma that has returned after treatment?
This phase 1/2 study evaluated daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed-refracto…
A new three-drug combination of daratumumab, lenalidomide, and dexamasone showed safety and response in people with relapsed multiple myelom…